These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 9362156)

  • 1. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
    Lode HN; Xiang R; Varki NM; Dolman CS; Gillies SD; Reisfeld RA
    J Natl Cancer Inst; 1997 Nov; 89(21):1586-94. PubMed ID: 9362156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A recombinant antibody-interleukin 2 fusion protein suppresses growth of hepatic human neuroblastoma metastases in severe combined immunodeficiency mice.
    Sabzevari H; Gillies SD; Mueller BM; Pancook JD; Reisfeld RA
    Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9626-30. PubMed ID: 7937818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
    Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
    Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12.
    Lode HN; Xiang R; Duncan SR; Theofilopoulos AN; Gillies SD; Reisfeld RA
    Proc Natl Acad Sci U S A; 1999 Jul; 96(15):8591-6. PubMed ID: 10411920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma.
    Lode HN; Dreier T; Xiang R; Varki NM; Kang AS; Reisfeld RA
    Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2475-80. PubMed ID: 9482910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lacking immunocytological GD2 expression in neuroblastoma: report of 3 cases.
    Schumacher-Kuckelkorn R; Hero B; Ernestus K; Berthold F
    Pediatr Blood Cancer; 2005 Aug; 45(2):195-201. PubMed ID: 15800908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy.
    Terzic T; Cordeau M; Herblot S; Teira P; Cournoyer S; Beaunoyer M; Peuchmaur M; Duval M; Sartelet H
    Pediatr Dev Pathol; 2018; 21(4):355-362. PubMed ID: 29067879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy.
    Lode HN; Xiang R; Dreier T; Varki NM; Gillies SD; Reisfeld RA
    Blood; 1998 Mar; 91(5):1706-15. PubMed ID: 9473237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with interleukin-2 and antitumor monoclonal antibodies.
    Sondel PM; Hank JA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S121-7. PubMed ID: 9457407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
    Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; K√ľnkele A
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2.
    Pancook JD; Becker JC; Gillies SD; Reisfeld RA
    Cancer Immunol Immunother; 1996 Feb; 42(2):88-92. PubMed ID: 8620525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2.
    Zeng Y; Jiang J; Huebener N; Wenkel J; Gaedicke G; Xiang R; Lode HN
    Cancer Lett; 2005 Oct; 228(1-2):187-93. PubMed ID: 15953676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
    Yu AL; Gilman AL; Ozkaynak MF; London WB; Kreissman SG; Chen HX; Smith M; Anderson B; Villablanca JG; Matthay KK; Shimada H; Grupp SA; Seeger R; Reynolds CP; Buxton A; Reisfeld RA; Gillies SD; Cohn SL; Maris JM; Sondel PM;
    N Engl J Med; 2010 Sep; 363(14):1324-34. PubMed ID: 20879881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.
    Parsons K; Bernhardt B; Strickland B
    Ann Pharmacother; 2013 Feb; 47(2):210-8. PubMed ID: 23386066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammatory response and treatment tolerance of long-term infusion of the anti-GD
    Ceylan K; Jahns LJ; Lode BN; Ehlert K; Kietz S; Troschke-Meurer S; Siebert N; Lode HN
    Pediatr Blood Cancer; 2018 Jun; 65(6):e26967. PubMed ID: 29350486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
    Seidel D; Shibina A; Siebert N; Wels WS; Reynolds CP; Huebener N; Lode HN
    Cancer Immunol Immunother; 2015 May; 64(5):621-34. PubMed ID: 25711293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disialoganglioside directed immunotherapy of neuroblastoma.
    Modak S; Cheung NK
    Cancer Invest; 2007 Feb; 25(1):67-77. PubMed ID: 17364560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD
    Mueller I; Ehlert K; Endres S; Pill L; Siebert N; Kietz S; Brock P; Garaventa A; Valteau-Couanet D; Janzek E; Hosten N; Zinke A; Barthlen W; Varol E; Loibner H; Ladenstein R; Lode HN
    MAbs; 2018 Jan; 10(1):55-61. PubMed ID: 29120699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.
    Frost JD; Hank JA; Reaman GH; Frierdich S; Seeger RC; Gan J; Anderson PM; Ettinger LJ; Cairo MS; Blazar BR; Krailo MD; Matthay KK; Reisfeld RA; Sondel PM
    Cancer; 1997 Jul; 80(2):317-33. PubMed ID: 9217046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disaloganglioside GD2 loss following monoclonal antibody therapy is rare in neuroblastoma.
    Kramer K; Gerald WL; Kushner BH; Larson SM; Hameed M; Cheung NK
    Med Pediatr Oncol; 2001 Jan; 36(1):194-6. PubMed ID: 11464881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.